ICVD | IHD | VTE | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariable | Univariate | Multivariable | Univariate | Multivariable | |||||||
Risk factor | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value |
Age, years | 1.05 (1.03 to 1.07) | 2.4 × 10−6 | 1.04 (1.02 to 1.07) | 0.0007 | 1.07 (1.05 to 1.10) | 7.0 × 10−12 | 1.06 (1.04 to 1.09) | 6.5 × 10−8 | 1.02 (1.00 to 1.03) | 0.03 | 1.01 (1.00 to 1.03) | |
Female | 1.0 (0.5 to 2.6) | 1.4 (0.6 to 3.8) | 0.5 (0.3 to 1.0) | 0.04 | 0.7 (0.3 to 1.5) | 0.9 (0.5 to 1.8) | 1.0 (0.5 to 2.1) | |||||
Smoking ever | 1.3 (0.8 to 2.3) | 2.1 (1.2 to 3.6) | 0.006 | 1.9 (1.0 to 3.5) | 0.04 | 0.8 (0.5 to 1.2) | ||||||
Hypertension treatment ± | 4.8 (2.8 to 8.5) | 2.7 × 10−8 | 3.7 (2.0 to 6.8) | 1.8 × 10−5 | 3.6 (2.2 to 6.2) | 1.4 × 10−6 | 2.3 (1.3 to 4.1) | 0.005 | 1.6 (1.0 to 2.5) | 0.05 | 1.3 (0.8 to 2.1) | |
Diabetes | 1.4 (0.4 to 3.7) | 5.5 (2.4 to 12.1) | 3.0 × 10−5 | 3.2 (1.3 to 7.8) | 0.009 | 0.8 (0.3 to 2.4) | ||||||
SLE duration, years | 1.06 (1.03 to 1.08) | 9.3 × 10−7 | 1.03 (1.00 to 1.06) | 0.02 | 1.05 (1.03 to 1.07) | 1.6 × 10−5 | 1.02 (0.99 to 1.04) | 1.00 (0.98 to 1.02) | ||||
STAT4 risk alleles* | ||||||||||||
1 or 2 vs 0 risk alleles | 2.9 (1.6 to 5.5) | 0.0009 | 3.3 (1.7 to 6.7) | 0.0006 | 1.05 (0.6 to 1.8) | 1.2 (0.7 to 2.1) | 1.3 (0.8 to 2.1) | 1.3 (0.8 to 2.1) | ||||
1 vs 0 risk alleles | 2.3 (1.2 to 4.6) | 0.01 | 0.9 (0.5 to 1.6) | 1.3 (0.8 to 2.0) | ||||||||
2 vs 0 risk alleles | 5.3 (2.5 to 11.7) | 2.5 × 10−5 | 1.5 (0.7 to 3.1) | 1.6 (0.8 to 3.0) | ||||||||
2 vs 1 risk allele | 2.3 (1.2 to 4.5) | 0.02 | 2.0 (0.9 to 4.0) | 1.3 (0.6 to 2.4) | ||||||||
aCL IgG | 2.5 (1.4 to 4.4) | 0.002 | 2.6 (1.3 to 4.9) | 0.005 | 0.6 (0.3 to 1.3) | 2.5 (1.5 to 4.0) | 0.0003 | |||||
aCL IgM | 1.3 (0.7 to 2.3) | 1.8 (1.0 to 3.1) | 0.04 | 1.8 (0.9 to 3.3) | 1.4 (0.8 to 2.3) | |||||||
as2GP-1 | 2.0 (1.1 to 3.5) | 0.02 | 0.7 (0.4 to 1.4) | 2.5 (1.6 to 4.1) | 0.0002 | |||||||
aPT | 2.0 (1.0 to 3.8) | 0.04 | 0.8 (0.3 to 1.7) | 1.5 (0.8 to 2.6) | ||||||||
≥2aPL | 2.4 (1.3 to 4.1) | 0.003 | 1.0 (0.5 to 1.9) | 2.6 (1.6 to 4.1) | 0.0001 | 2.5 (1.5 to 4.1) | 0.0002 | |||||
Mid Sweden vs southern Sweden | 0.9 (0.5 to 1.6) | 1.0 (0.7 to 1.3) | 1.3 (0.8 to 2.3) | 1.0 (0.7 to 1.3) | 0.8 (0.6 to 1.0) | 0.05 | 0.8 (0.6 to 1.0) |
p Values. 0.05 are presented.
↵* Number of STAT4 rs10181656(G), risk alleles (0,1 or 2).
≥2aPL: two or more positive tests among aCL IgG, aCL IgM, aβ2GP-1 or aPT; a, anti; β2GP-1, β2 glycoprotein 1; CL, cardiolipin, ICVD, ischaemic cerebrovascular disease; IHD, ischaemic heart disease; PL, phospholipids; PT, prothrombin; SLE< systemic lupus erythematosus; VTE, venous thromboembolism.